Back
Rate this talk
Your peers rated this 5 stars
1-minute watch | Talk 1 of 3

EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

Series trailer

Dr Eva Wagner-Drouet, Dr Miguel-Angel Perales
TRAILER
EBMT

Trailer for the EBMT symposium, entitled 'How has CAR T changed the R/R DLBCL treatment landscape?' featuring Dr Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, USA and Dr Eva Wagner-Drouet, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany

Read more

Talks in this series

Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch | Talk 1 of 3
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Series trailer
Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

Series trailer

Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch | Talk 2 of 3
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Miguel-Angel Perales

Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch | Talk 3 of 3
Redefining the treatment paradigm in 2L DLBCL
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch

Redefining the treatment paradigm in 2L DLBCL

Dr Eva Wagner-Drouet

Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch | Talk 1 of 3
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Series trailer
Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

Series trailer

Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch | Talk 2 of 3
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Miguel-Angel Perales

Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch | Talk 3 of 3
Redefining the treatment paradigm in 2L DLBCL
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch

Redefining the treatment paradigm in 2L DLBCL

Dr Eva Wagner-Drouet

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.